Published in PLoS One on November 12, 2010
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev (2011) 2.25
Functions of autophagy in normal and diseased liver. Autophagy (2013) 1.81
An image analysis toolbox for high-throughput C. elegans assays. Nat Methods (2012) 1.48
Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology (2013) 1.34
Autonomous screening of C. elegans identifies genes implicated in synaptogenesis. Nat Methods (2012) 1.26
Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. PLoS Negl Trop Dis (2012) 1.19
Hepatic fibrosis and carcinogenesis in α1-antitrypsin deficiency: a prototype for chronic tissue damage in gain-of-function disorders. Cold Spring Harb Perspect Biol (2011) 1.07
Mysteries of α1-antitrypsin deficiency: emerging therapeutic strategies for a challenging disease. Dis Model Mech (2014) 1.02
Development and validation of an automated high-throughput system for zebrafish in vivo screenings. PLoS One (2012) 1.01
WormScan: a technique for high-throughput phenotypic analysis of Caenorhabditis elegans. PLoS One (2012) 1.01
A microfluidic device for whole-animal drug screening using electrophysiological measures in the nematode C. elegans. Lab Chip (2012) 1.01
Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency. J Biol Chem (2012) 0.98
A pro-cathepsin L mutant is a luminal substrate for endoplasmic-reticulum-associated degradation in C. elegans. PLoS One (2012) 0.97
C. elegans in high-throughput drug discovery. Adv Drug Deliv Rev (2013) 0.93
An ultra high-throughput, whole-animal screen for small molecule modulators of a specific genetic pathway in Caenorhabditis elegans. PLoS One (2013) 0.90
QuantWorm: a comprehensive software package for Caenorhabditis elegans phenotypic assays. PLoS One (2014) 0.90
Fluphenazine reduces proteotoxicity in C. elegans and mammalian models of alpha-1-antitrypsin deficiency. PLoS One (2014) 0.88
Multi-step usage of in vivo models during rational drug design and discovery. Int J Mol Sci (2011) 0.87
Proteostasis: a new therapeutic paradigm for pulmonary disease. Proc Am Thorac Soc (2011) 0.86
A high-content screening assay in transgenic zebrafish identifies two novel activators of fgf signaling. Birth Defects Res C Embryo Today (2011) 0.86
Innovation in academic chemical screening: filling the gaps in chemical biology. Curr Opin Chem Biol (2013) 0.85
Targeting intracellular degradation pathways for treatment of liver disease caused by α1-antitrypsin deficiency. Pediatr Res (2013) 0.85
Worms, flies and four-legged friends: the applicability of biological models to the understanding of intestinal inflammatory diseases. Dis Model Mech (2011) 0.85
Capitalizing on the autophagic response for treatment of liver disease caused by alpha-1-antitrypsin deficiency and other genetic diseases. Biomed Res Int (2014) 0.83
Caenorhabditis elegans-based model systems for antifungal drug discovery. Curr Pharm Des (2011) 0.82
A genome-wide RNAi screen identifies potential drug targets in a C. elegans model of α1-antitrypsin deficiency. Hum Mol Genet (2014) 0.81
Novel treatment strategies for liver disease due to α1-antitrypsin deficiency. Clin Transl Sci (2012) 0.81
Induced pluripotent stem cells model personalized variations in liver disease resulting from α1-antitrypsin deficiency. Hepatology (2015) 0.80
Light microscopy applications in systems biology: opportunities and challenges. Cell Commun Signal (2013) 0.80
The struggle by Caenorhabditis elegans to maintain proteostasis during aging and disease. Biol Direct (2016) 0.80
Using Caenorhabditis elegans as a model system to study protein homeostasis in a multicellular organism. J Vis Exp (2013) 0.79
Non-microfluidic methods for imaging live C. elegans. Methods (2014) 0.79
A C. elegans model of human α1-antitrypsin deficiency links components of the RNAi pathway to misfolded protein turnover. Hum Mol Genet (2014) 0.79
A bacterial metabolite induces glutathione-tractable proteostatic damage, proteasomal disturbances, and PINK1-dependent autophagy in C. elegans. Cell Death Dis (2015) 0.77
Disorders of protein misfolding: alpha-1-antitrypsin deficiency as prototype. J Pediatr (2013) 0.77
Stem cells: a model for screening, discovery and development of drugs. Stem Cells Cloning (2011) 0.76
Detection of Autophagy in Caenorhabditis elegans Using GFP::LGG-1 as an Autophagy Marker. Cold Spring Harb Protoc (2016) 0.76
In vitro inflammation inhibition model based on semi-continuous toll-like receptor biosensing. PLoS One (2014) 0.76
High-throughput screening in the C. elegans nervous system. Mol Cell Neurosci (2016) 0.75
High-throughput fluorescence imaging approaches for drug discovery using in vitro and in vivo three-dimensional models. Expert Opin Drug Discov (2015) 0.75
Liver tumors in children with metabolic disorders. Transl Pediatr (2015) 0.75
Ageing in worms: N-acylethanolamines take control. Protein Cell (2011) 0.75
The aggregation-prone intracellular serpin SRP-2 fails to transit the ER in Caenorhabditis elegans. Genetics (2015) 0.75
Clozapine Modulates Glucosylceramide, Clears Aggregated Proteins, and Enhances ATG8/LC3 in Caenorhabditis elegans. Neuropsychopharmacology (2016) 0.75
Worming our way to Alzheimer's disease drug discovery. Biol Psychiatry (2013) 0.75
α1-antitrypsin deficiency and the hepatocytes - an elegans solution to drug discovery. Int J Biochem Cell Biol (2013) 0.75
Expanding the C. elegans toolbox into a toolshed. Methods (2014) 0.75
Large-scale microfluidics providing high-resolution and high-throughput screening of Caenorhabditis elegans poly-glutamine aggregation model. Nat Commun (2016) 0.75
Deficient and Null Variants of SERPINA1 Are Proteotoxic in a Caenorhabditis elegans Model of α1-Antitrypsin Deficiency. PLoS One (2015) 0.75
A High-Throughput Small Molecule Screen for C. elegans Linker Cell Death Inhibitors. PLoS One (2016) 0.75
Novel animal model defines genetic contributions for neuron-to-neuron transfer of α-synuclein. Sci Rep (2017) 0.75
Approaches for Studying Autophagy in Caenorhabditis elegans. Cells (2017) 0.75
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
Adapting proteostasis for disease intervention. Science (2008) 13.22
Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science (2003) 9.17
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol (2007) 8.08
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol (2005) 7.11
An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science (2010) 6.47
Opposing activities protect against age-onset proteotoxicity. Science (2006) 5.85
Statistical practice in high-throughput screening data analysis. Nat Biotechnol (2006) 5.85
The mec-4 gene is a member of a family of Caenorhabditis elegans genes that can mutate to induce neuronal degeneration. Nature (1991) 5.30
Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol (2000) 5.14
The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A (2002) 4.25
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat Chem Biol (2008) 4.19
Finding function in novel targets: C. elegans as a model organism. Nat Rev Drug Discov (2006) 3.64
Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet (2000) 3.64
Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science (2010) 3.60
Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci U S A (2007) 3.37
Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A (1995) 3.36
Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen (2003) 3.15
Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov (2003) 2.81
Dual roles of autophagy in the survival of Caenorhabditis elegans during starvation. Genes Dev (2007) 2.80
Intracellular inclusions containing mutant alpha1-antitrypsin Z are propagated in the absence of autophagic activity. J Biol Chem (2005) 2.60
Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov (2010) 2.58
Novel trends in high-throughput screening. Curr Opin Pharmacol (2009) 2.23
A small-molecule screen in C. elegans yields a new calcium channel antagonist. Nature (2006) 2.19
An antidepressant that extends lifespan in adult Caenorhabditis elegans. Nature (2007) 2.15
Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog (2007) 2.05
Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem (2008) 1.99
High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol (2009) 1.99
Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A (2003) 1.90
Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res (2007) 1.88
Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol (2009) 1.88
Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest (2002) 1.84
Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci U S A (1999) 1.84
Caenorhabditis elegans: a versatile platform for drug discovery. Biotechnol J (2006) 1.72
Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem (2003) 1.70
An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury. Cell (2007) 1.56
A reduction in intestinal cell pHi due to loss of the Caenorhabditis elegans Na+/H+ exchanger NHX-2 increases life span. J Biol Chem (2003) 1.52
Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med (2010) 1.48
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol (2007) 1.40
An automated high-throughput assay for survival of the nematode Caenorhabditis elegans. Free Radic Biol Med (2003) 1.38
High-throughput screening and small animal models, where are we? Br J Pharmacol (2010) 1.37
Chemically defined medium and Caenorhabditis elegans. BMC Biotechnol (2003) 1.37
HTS and hit finding in academia--from chemical genomics to drug discovery. Drug Discov Today (2009) 1.32
Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. J Mol Biol (2009) 1.31
Cellular platforms for HTS: three case studies. Drug Discov Today (2002) 1.30
The NHX family of Na+-H+ exchangers in Caenorhabditis elegans. J Biol Chem (2002) 1.27
Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS One (2009) 1.22
ADMET--turning chemicals into drugs. Nat Biotechnol (2001) 1.21
C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp Gerontol (2006) 1.20
Molecular and cellular aspects of protein misfolding and disease. FASEB J (2008) 1.14
Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol (2008) 1.14
Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. Hum Mol Genet (2001) 1.08
Systems cell biology based on high-content screening. Methods Enzymol (2006) 1.07
Modeling molecular and cellular aspects of human disease using the nematode Caenorhabditis elegans. Pediatr Res (2009) 1.07
Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol (2007) 1.07
High-content screening moves to the front of the line. Drug Discov Today (2006) 1.05
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol (2009) 1.02
Strategies for the inhibition of protein aggregation in human diseases. Chembiochem (2010) 0.98
High-content screening: emerging hardware and software technologies. Methods Enzymol (2006) 0.96
Molecular mousetraps and the serpinopathies. Biochem Soc Trans (2005) 0.95
Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors. Methods Enzymol (2006) 0.93
Caenorhabditis elegans as a model for lysosomal storage disorders. Biochim Biophys Acta (2008) 0.90
Temperature-sensitive mutant of the Caenorhabditis elegans neurotoxic MEC-4(d) DEG/ENaC channel identifies a site required for trafficking or surface maintenance. J Biol Chem (2005) 0.89
Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases. Arch Neurol (2010) 0.89
Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform. Methods Enzymol (2006) 0.88
ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters. Bioorg Med Chem (2009) 0.88
Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation. Methods Enzymol (2006) 0.86
Screening for presenilin inhibitors using the free-living nematode, Caenorhabditis elegans. J Biomol Screen (2004) 0.81
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science (2010) 6.47
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Intracellular inclusions containing mutant alpha1-antitrypsin Z are propagated in the absence of autophagic activity. J Biol Chem (2005) 2.60
Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene (2003) 2.57
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res (2009) 2.32
An overview of the serpin superfamily. Genome Biol (2006) 2.14
Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn (2009) 2.11
Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology (2005) 2.05
Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther (2007) 1.95
Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response. J Biol Chem (2005) 1.93
Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol (2009) 1.88
Functions of autophagy in normal and diseased liver. Autophagy (2013) 1.81
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J Biol Chem (2008) 1.74
An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury. Cell (2007) 1.56
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol (2007) 1.40
Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg Med Chem (2005) 1.40
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol (2008) 1.38
22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem (2003) 1.37
Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem (2002) 1.37
Transcriptome profiling of the small intestinal epithelium in germfree versus conventional piglets. BMC Genomics (2007) 1.35
Serpins flex their muscle: I. Putting the clamps on proteolysis in diverse biological systems. J Biol Chem (2010) 1.32
The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem (2005) 1.31
The substrate recognition domains of the N-end rule pathway. J Biol Chem (2008) 1.31
Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc 25 C. Oncogene (2005) 1.30
The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther (2005) 1.29
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res (2007) 1.28
Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta (2010) 1.25
Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol (2008) 1.21
Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol (2010) 1.20
Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov (2002) 1.19
Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency. Hepatology (2004) 1.18
Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. Annu Rev Pharmacol Toxicol (2005) 1.18
Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem Biol (2009) 1.18
Serpins flex their muscle: II. Structural insights into target peptidase recognition, polymerization, and transport functions. J Biol Chem (2010) 1.14
Grp78, Grp94, and Grp170 interact with alpha1-antitrypsin mutants that are retained in the endoplasmic reticulum. Am J Physiol Gastrointest Liver Physiol (2005) 1.14
Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem (2009) 1.14
Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol (2008) 1.14
Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis (2009) 1.14
TGF-beta-activated kinase 1 and TAK1-binding protein 1 cooperate to mediate TGF-beta1-induced MKK3-p38 MAPK activation and stimulation of type I collagen. Am J Physiol Renal Physiol (2007) 1.14
Update of the human and mouse SERPIN gene superfamily. Hum Genomics (2013) 1.12
Transforming growth factor-beta (TGF-beta1) activates TAK1 via TAB1-mediated autophosphorylation, independent of TGF-beta receptor kinase activity in mesangial cells. J Biol Chem (2009) 1.12
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther (2010) 1.11
Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob Agents Chemother (2005) 1.11
Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice. J Clin Invest (2010) 1.11
Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol (2009) 1.11
A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS Negl Trop Dis (2010) 1.10
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther (2008) 1.10
Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev Technol (2010) 1.10
Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS One (2013) 1.07
Hepatic fibrosis and carcinogenesis in α1-antitrypsin deficiency: a prototype for chronic tissue damage in gain-of-function disorders. Cold Spring Harb Perspect Biol (2011) 1.07
Modeling molecular and cellular aspects of human disease using the nematode Caenorhabditis elegans. Pediatr Res (2009) 1.07
Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol (2007) 1.07
Fasting in alpha1-antitrypsin deficient liver: constitutive [correction of consultative] activation of autophagy. Am J Physiol Gastrointest Liver Physiol (2002) 1.06
Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. Chem Biol (2013) 1.05
Cellular analysis of disorazole C and structure-activity relationship of analogs of the natural product. Chem Biol Drug Des (2006) 1.05
Protein phosphatase 2A is a negative regulator of transforming growth factor-beta1-induced TAK1 activation in mesangial cells. J Biol Chem (2008) 1.05
Redox regulation of Cdc25B by cell-active quinolinediones. Mol Pharmacol (2005) 1.04
Regulator of G Signaling 16 is a marker for the distinct endoplasmic reticulum stress state associated with aggregated mutant alpha1-antitrypsin Z in the classical form of alpha1-antitrypsin deficiency. J Biol Chem (2007) 1.04
Mysteries of α1-antitrypsin deficiency: emerging therapeutic strategies for a challenging disease. Dis Model Mech (2014) 1.02
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol (2009) 1.02
Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione. J Biol Chem (2002) 1.02
Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nat Protoc (2007) 1.01
Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res (2007) 1.01
Design, Synthesis, and Biological Evaluation of PKD Inhibitors. Pharmaceutics (2011) 0.99
Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem Biol (2003) 0.99
NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors. J Pharmacol Exp Ther (2004) 0.99
Use of an electronic alert to identify patients with acute kidney injury. Clin Med (2014) 0.99
Clathrin pit-mediated endocytosis of neutrophil elastase and cathepsin G by cancer cells. J Biol Chem (2012) 0.98
Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21. Cell Cycle (2009) 0.98
A pro-cathepsin L mutant is a luminal substrate for endoplasmic-reticulum-associated degradation in C. elegans. PLoS One (2012) 0.97
Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D. ACS Med Chem Lett (2011) 0.97
The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases. Biochemistry (2002) 0.97